Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP1056 | DOI: 10.1530/endoabs.49.EP1056

1Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Department of Clinical Medicine and Surgery, Endocrinology Unit, University of Naples Federico II, Naples, Italy; 3Department of Medicine (DIMED), Division of Endocrinology, University of Padua, Padua, Italy; 4Biomedical Department of Internal and Specialist Medicine (DIBIMIS), Section of Cardio-Respiratory and Endocrine-Metabolic Diseases, University of Palermo, Palermo, Italy; 5Department of Economics, University of Messina, Messina, Italy; 6Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy.

: Patients with Cushing’s disease (CD) have increased cardiovascular risk due to metabolic alterations caused by glucocorticoids excess. Pasireotide, a multireceptor-targeted somatostatin analogue, is a therapeutic option in CD patients in whom surgery is not curative or not feasible. Pasireotide has been shown to be effective in controlling hypercortisolism and to improve metabolic features. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardio-metabolic risk. We aimed to assess the effects of 12-month pasireotide therapy on cardio-metabolic and cardiovascular risk in CD patients. In 16 CD patients (11 females), referred to the Endocrine Units of four Italian University Hospitals, we assessed anthropometric, clinical and biochemical parameters and calculated VAI, ATD severity, Framingham and Atherosclerotic CardioVascular Disease Risk Scores (FRS and ASCVD respectively), at baseline and after 6 and 12 months of therapy with pasireotide (1200–1800 mcg/daily). Before starting pasireotide therapy, ATD was present in 8/16 patients (severe in 2/16, mild in 2/16, moderate in 3/16). After 12 months of treatment: i) UFC levels (P=0.003), BMI (P<0.001), waist circumference (P=0.001), LDL-cholesterol (P=0.033), total-cholesterol (P=0.032), triglycerides (P=0.03), VAI (P=0.015) and ATD severity (P=0.026) were significantly decreased as compared to baseline; ii) ATD was present in only 1/16 patients; iii) prevalence of diabetes (P=0.015) and HbA1c levels (P=0.001) were significantly increased as compared to baseline; iv) FRS and ASCVD scores were not statistically different from pre-treatment values. In conclusion, twelve-month pasireotide treatment reduces cardio-metabolic risk in CD patients.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.